Alembic Pharma Ko USFDA Ka Green Signal! Parkinson's Drug Ko Manzoori, Par Share Gir Gaya?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Alembic Pharma Ko USFDA Ka Green Signal! Parkinson's Drug Ko Manzoori, Par Share Gir Gaya?
Overview

Alembic Pharma ke liye ek mixed news hai, bhai log! Unko Parkinson's ki Carbidopa, Levodopa, Entacapone tablets ke liye USFDA se final approval mil gayi hai. Ye unki **234th** ANDA approval hai, jo US market ke liye kaafi important hai. Lekin, Q4 results mein profit thoda **4.1%** down raha due to ek special expense, aur stock bhi **2.45%** gir gaya.

USFDA Ka Approval Toh Mil Gaya!

Alembic Pharmaceuticals ne ek aur milestone achieve kiya hai, yaar. Unko Parkinson's disease ki Carbidopa, Levodopa, aur Entacapone tablets ke liye USFDA se final approval mil gayi hai. Ye unki 234th Abbreviated New Drug Application (ANDA) approval hai, jismein 214 final aur 20 tentative approvals hain. Matlab, company US generics market mein apni pakad strong kar rahi hai.

Par Profits Ka Kya Scene Hai?

Abhi, company ne Q4 FY25 results announce kiye hain. Revenue mein 10.8% ka jump dikha aur yeh ₹1,876.3 crore ho gaya. EBITDA bhi 12.8% badhkar ₹293.5 crore raha, margins bhi 15.6% tak pahunch gaye. Lekin, Net Profit 4.1% ghat kar ₹132 crore ho gaya. Iska reason tha ek ₹42 crore ka one-time expense jo employee benefits par hua. Is mixed result ki wajah se, February 6, 2026 ko stock price 2.45% gir kar ₹790.60 par aa gaya. Last 6 mahine mein stock 16.63% gir chuka hai.

Market Opportunity Aur Valuation Ka Game

Parkinson's drug market kafi bada hai, globally USD 7.75 billion ka estimate hai 2025 mein aur growth bhi expected hai. US generics market bhi 3.3% CAGR se grow karega 2034 tak. Lekin, Alembic ka Return on Capital Employed (ROCE) 13.05% hai, jo peers like Dr. Reddy's (22.7%), Cipla (22.7%), aur Sun Pharma (20.2%) se kam hai. Competing companies jaise Sun Pharma ka P/E ratio 33.5x hai aur Dr. Reddy's ka 18.5x hai, jabki Alembic ka 25-27x ke aas-paas chal raha hai. Company ka sales growth bhi pichhle 5 saal mein 7.69% raha hai aur return on equity 10.6% (3 saal mein).

Analyst Kya Bol Rahe Hain?

Market aur sector ke liye outlook filhaal theek-thaak hai. FY26 mein Indian pharma sector 7-9% grow kar sakta hai, par US market mein price erosion aur regulation ke karan 3-5% hi growth expected hai. Fir bhi, analysts ka Alembic par bharosa hai, unka average target price ₹1,047 ke aas-paas hai, matlab almost 30% upside ka potential. Pichhle approvals par stock ne reaction dikhaya tha, par abhi waale approval par market zyada focus profit growth par kar raha hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.